Visseren FLJ - Search Results

1

Generalisability of trials on antithrombotic treatment intensification in patients with cardiovascular disease.

Castelijns MC, Hageman SHJ, Teraa M, van der Meer MG, Westerink J, Ten Berg J, Visseren FLJ. Castelijns MC, et al. Among authors: visseren flj. Heart. 2024 Mar 12;110(7):482-490. doi: 10.1136/heartjnl-2023-323519. Heart. 2024. PMID: 38182277

2

Levels of homocysteine are increased in metabolic syndrome patients but are not associated with an increased cardiovascular risk, in contrast to patients without the metabolic syndrome.

Hajer GR, van der Graaf Y, Olijhoek JK, Verhaar MC, Visseren FL; SMART Study Group. Hajer GR, et al. Heart. 2007 Feb;93(2):216-20. doi: 10.1136/hrt.2006.093971. Epub 2006 Sep 4. Heart. 2007. PMID: 16952974 Free PMC article.

3

Unrecognised myocardial infarction in subjects at high vascular risk: prevalence and determinants.

Meijs MF, Bots ML, Cramer MJ, Vonken EJ, Velthuis BK, van der Graaf Y, Visseren FL, Mali WP, Doevendans PA; SMART Study group. Meijs MF, et al. Heart. 2009 May;95(9):728-32. doi: 10.1136/hrt.2008.157727. Epub 2009 Feb 12. Heart. 2009. PMID: 19218261

4

Letter by Westerink and Visseren regarding article, "Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation".

Westerink J, Visseren FL. Westerink J, et al. Circulation. 2009 Sep 1;120(9):e66; author reply e69-70. doi: 10.1161/CIRCULATIONAHA.109.857730. Circulation. 2009. PMID: 19720942 No abstract available.

5

Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.

Westerink J, Visseren FL. Westerink J, et al. Eur J Clin Invest. 2010 Jan;40(1):87. doi: 10.1111/j.1365-2362.2009.02222.x. Epub 2009 Nov 12. Eur J Clin Invest. 2010. PMID: 19912317 No abstract available.

6

Increased visceral adipose tissue mass is associated with increased C-reactive protein in patients with manifest vascular diseases.

Faber DR, van der Graaf Y, Westerink J, Visseren FL. Faber DR, et al. Atherosclerosis. 2010 Sep;212(1):274-80. doi: 10.1016/j.atherosclerosis.2010.04.029. Epub 2010 May 21. Atherosclerosis. 2010. PMID: 20494358

7

Vascular and metabolic effects of 12 days intensive walking to Santiago de Compostela.

Bemelmans RH, Coll B, Faber DR, Westerink J, Blommaert PP, Spiering W, Visseren FL. Bemelmans RH, et al. Atherosclerosis. 2010 Oct;212(2):621-7. doi: 10.1016/j.atherosclerosis.2010.06.012. Epub 2010 Jun 11. Atherosclerosis. 2010. PMID: 20598693

8

The relation between thyroid-stimulating hormone and measures of adiposity in patients with manifest vascular disease.

Westerink J, van der Graaf Y, Faber DR, Visseren FL; SMART study group. Westerink J, et al. Eur J Clin Invest. 2011 Feb;41(2):159-66. doi: 10.1111/j.1365-2362.2010.02391.x. Epub 2010 Oct 8. Eur J Clin Invest. 2011. PMID: 21039443

9

Pharmacological and non-pharmacological interventions to influence adipose tissue function.

Westerink J, Visseren FL. Westerink J, et al. Cardiovasc Diabetol. 2011 Jan 28;10:13. doi: 10.1186/1475-2840-10-13. Cardiovasc Diabetol. 2011. PMID: 21276223 Free PMC article. Review.

10

Relation between thyroid-stimulating hormone and the occurrence of cardiovascular events and mortality in patients with manifest vascular diseases.

Westerink J, van der Graaf Y, Faber DR, Spiering W, Visseren FL; SMART study group. Westerink J, et al. Eur J Prev Cardiol. 2012 Aug;19(4):864-73. doi: 10.1177/1741826711416045. Epub 2011 Jul 1. Eur J Prev Cardiol. 2012. PMID: 21724680

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

484 results

Search Page

Filters